The Latest Breaking News from AbbVie

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

AbbVie just increased its dividend by 5.5%, raising the quarterly payout to $1.73 per share starting February 2026, reflecting strong confidence in its long-term growth driven by new drugs like Skyrizi and Rinvoq.

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

AbbVie beats earnings and raises guidance as Skyrizi and Rinvoq fuel growth, setting the stage for ABBV stock to hold $250 as a new floor

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential